IL6 and osteosarcoma: Furthermore, Han et al. reported that osteosarcoma cells become more sensitive to cisplatin when IL-6 production is reduced 21; however, little is known about the relationship between IL-6 expression and the clinicopathological characteristics of patients with osteosarcoma.